Endocrine Abstracts

Objective: To evaluate the efficacy of canagliflozin 100 mg for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.

Patients and methods: Descriptive study: patients with type 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and canagliflozin 100 mg is added. Variables analyzed baseline and at 6 months after treatment change: age, sex, time of diabetes evolution, Body mass index (BMI), abdominal perimeter (BP), systolic blood pressure (SBP), diastolic blood pressure (DBP), LDL, HDL, triglycerides (TG), uric acid (UA). Statistical analysis: comparing means with Student’s test.

Results: Eighteen patients. 50% women Age: 55.61±7.1 years. Time of diabetes evolution: 7.7±5 years. Weight loss achieved 6 months after the change of treatment was 6±2.5 Kg. No side effects were recorded. The treatment change was satisfactory for all patients.

Conclusions: The change of treatment of liraglutide 1.8 mg to canagliflozin 100 mg in patients with optimal glycemic control and stabilization weight loss, achieves a progression in weight loss and improves the metabolic control of the patient with DM-2. The change of treatment was satisfactory for all patients. No side effects were recorded.